Its use was approved in December 2012 by the U.S. Food and Drug Administration (FDA) for use in tuberculosis (TB) treatment, as part of a Fast-Track accelerated approval, for use only in cases of multidrug-resistant tuberculosis, and the more resistant extensively drug resistant tuberculosis. both the World Health Organization (WHO) and US Centers for Disease Control (CDC) have recommended (provisionally) that<unk>  be reserved for people with multidrug-resistant tuberculosis when an otherwise recommended regimen cannot be designed. Clinical trials<unk>  has been studied in phase IIb studies for the treatment of multidrug-resistant tuberculosis while phase III studies are currently underway. It has been shown to improve cure rates of smear-positive multidrug-resistant tuberculosis, though with some concern for increased rates of death (further detailed in the Adverse effects section). Small studies have also examined its use as salvage therapy for non-tuberculous mycobacterial infections. It is a component of the experimental BPaMZ combination treatment<unk>  + pretomanid + moxifloxacin + pyrazinamide).
Bedaquiline
Selegiline
Rasagiline
Perhexiline
Tetrabenazine
Deutetrabenazine
Butriptyline
3-Quinuclidinyl benzilate